Genomic testing can identify African American prostate cancer patients with high-risk disease

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.

July 17, 2026

Vol.52 No.28

By Paul Goldberg and Claire Marie Porter

Cancer Policy

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

Medicare Advantage beneficiaries have access to fewer cancer specialists, when compared to traditional Medicare beneficiaries, according to a study published in JAMA Network Open.

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

A growing number of prostate cancer experts argue that calling the lowest-risk prostate cancer “cancer” does more harm than good. A UCLA-led study found removing the cancer label could dramatically reduce overtreatment and encourage more men to get screened, potentially leading to significantly fewer deaths from aggressive prostate cancer.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Equal access to cancer care removes race as predictor of survival, VA analysis finds

A healthcare system designed to provide more consistent access to comprehensive multidisciplinary cancer care can help eliminate longstanding racial gaps in cancer survival in the United States, according to a study led by a UCLA-VA collaborative team.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Sexual orientation, gender identity are key variables in cancer screening disparities, OSUCCC – James study finds

Research has uncovered persistent disparities in preventive cancer care across different sexual orientation and gender identity populations. The study, conducted by researchers at The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, found particular concern for cervical and breast cancer screening.

July 10, 2026

Vol.52 No.27

Clinical Roundup

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Genomic testing can identify African American prostate cancer patients with high-risk disease

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

Equal access to cancer care removes race as predictor of survival, VA analysis finds

Sexual orientation, gender identity are key variables in cancer screening disparities, OSUCCC – James study finds

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Genomic testing can identify African American prostate cancer patients with high-risk disease

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the wayKnudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

Equal access to cancer care removes race as predictor of survival, VA analysis finds

Sexual orientation, gender identity are key variables in cancer screening disparities, OSUCCC – James study finds

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

Never miss an issue!

Login

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”